Overview

• Under the terms of the deal, Zydus will pay US$75 million upfront and up to US$50 million in milestone‐based payments over three years to acquire two manufacturing sites in Emeryville and Berkeley, California.
• The acquired facilities feature state‐of‐the‐art biologics manufacturing capabilities and an experienced workforce.
• Zydus’ new CDMO arm will provide end-to-end biologics development services from preclinical studies through clinical and commercial manufacturing.
• Zydus will serve as exclusive contract manufacturer for Agenus’ Phase-3 immuno-oncology candidates Botensilimab and Balstilimab, with first rights on future pipeline products.
• The global biologics CDMO market is expected to reach about US$84.9 billion by 2034, growing at a 15.7 percent CAGR, highlighting the strategic growth opportunity.